title: Guillain-Barré syndrome.
abstract: Guillain-Barré syndrome consists of a group of neuropathic conditions characterized by progressive weakness and diminished or absent myotatic reflexes. The estimated annual incidence in the United States is 1.65 to 1.79 per 100,000 persons. Guillain-Barré syndrome is believed to result from an aberrant immune response that attacks nerve tissue. This response may be triggered by surgery, immunizations, or infections. The most common form of the disease, acute inflammatory demyelinating polyradiculoneuropathy, presents as progressive motor weakness, usually beginning in the legs and advancing proximally. Symptoms typically peak within four weeks, then plateau before resolving. More than one-half of patients experience severe pain, and about two-thirds have autonomic symptoms, such as cardiac arrhythmias, blood pressure instability, or urinary retention. Advancing symptoms may compromise respiration and vital functions. Diagnosis is based on clinical features, cerebrospinal fluid testing, and nerve conduction studies. Cerebrospinal fluid testing shows increased protein levels but a normal white blood cell count. Nerve conduction studies show a slowing, or possible blockage, of conduction. Patients should be hospitalized for multidisciplinary supportive care and disease-modifying therapy. Supportive therapy includes controlling pain with nonsteroidal anti-inflammatory drugs, carbamazepine, or gabapentin; monitoring for respiratory and autonomic complications; and preventing venous thrombosis, skin breakdown, and deconditioning. Plasma exchange therapy has been shown to improve short-term and long-term outcomes, and intravenous immune globulin has been shown to hasten recovery in adults and children. Other therapies, including corticosteroids, have not demonstrated benefit. About 3 percent of patients with Guillain-Barré syndrome die. Neurologic problems persist in up to 20 percent of patients with the disease, and one-half of these patients are severely disabled.
authors: University of Kansas School of Medicine, Wichita, KS, USA.
authors: Anne D
authors: AD
authors: Walling
authors: Gretchen
authors: G
authors: Dickson
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D015984:Causality; D000075202:Contraindications; D003937:Diagnosis, Differential; D042241:Early Diagnosis; D005938:Glucocorticoids; D020275:Guillain-Barre Syndrome / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015994:Incidence; D007442:Intubation, Intratracheal; D009437:Neuralgia / Q000188:drug therapy / Q000209:etiology; D010951:Plasma Exchange; D011379:Prognosis; D012121:Respiration, Artificial; D053828:Stockings, Compression
chemical_list: D000925:Anticoagulants; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous